Erschienen in:
01.12.2005 | Adis Drug Profile
Ramelteon
A Viewpoint by Göran Hajak
verfasst von:
Göran Hajak
Erschienen in:
CNS Drugs
|
Ausgabe 12/2005
Einloggen, um Zugang zu erhalten
Excerpt
Physicians and experts dealing with the problem of disturbed sleep have recently woken up from a period of sleep that had lasted for years. Over a period of two decades, pharmacotherapy of insomnia was dominated by the use of pharmacological agents acting at benzodiazepine receptor sites in the human brain. These benzodiazepines and modern benzodiazepine receptor agonists, such as zolpidem, zaleplon and zopiclone, as well as old fashioned over-the-counter products of heterogeneous pharmacology (e.g. antihistamines, herbal drugs), were approved by health authorities for the treatment of insomnia. Additionally, physicians prescribed antidepressants (e.g. trazodone, doxepin) or antipsychotics (e.g. olanzapine, quetiapine) for off-label use as sleep-promoting agents. …